Science Immunology – Science

The PDF file includes:

  • Fig. S1. Representative plots from FACS.
  • Fig. S2. scRNA-seq map of individual suction blister donors.
  • Fig. S3. Feature plots of selected marker genes for the entire scRNA-seq dataset.
  • Fig. S4. scRNA-seq map of cell populations in untreated AD, dupilumab-treated AD, and healthy control suction blisters.
  • Fig. S5. Expression of down-regulated genes in dupilumab-treated AD skin.
  • Fig. S6. Expression of up-regulated genes in dupilumab-treated AD skin.
  • Fig. S7. Gene expression within the melanocyte cluster.
  • Fig. S8. Gene expression within LC and plasmacytoid DC clusters.
  • Fig. S9. Selected T cell marker gene expression.
  • Fig. S10. Expression of receptor components for IL-4 and IL-13 in T cell and DC clusters.
  • Fig. S11. Selected immune cell markers.
  • Fig. S12. Log2 NPX of individual serum samples for markers significantly increased at 1 year of dupilumab treatment compared with healthy control individuals for all time points.
  • Table S1. Baseline characteristics of patients and healthy controls included for skin suction blistering and skin biopsy sampling.
  • Table S2. Cell numbers, read numbers, and gene numbers.
  • Table S3. Cell numbers per patient and cell cluster.
  • Table S4. Top 10 differentially expressed genes (Clustermarker).
  • Legends for tables S5 to S10
  • Table S11. Percentages of IL13+, IL26+, IL22+, and IFNG+ cells, as percentages of all T2 cells (IL13+), T17 cells (IL26+), T22 cells (IL22+), and T1 cells (IFNG+).
  • Legend for table S12
  • Table S13. Baseline characteristics of patients used for serum sample analyses (multiplex proteomic assays).
  • Legends for tables S14 and S15

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of healthy controls versus AD untreated.
  • Table S6 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of 16 weeks dupilumab-treated AD versus AD untreated.
  • Table S7 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of 1 year dupilumab-treated AD versus AD untreated.
  • Table S8 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of 16 weeks of dupilumab-treated AD versus healthy controls.
  • Table S9 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of 1 year of dupilumab-treated AD versus healthy controls.
  • Table S10 (Microsoft Excel format). Differential gene expression analysis within cell types of scRNA-seq analyses; comparison of 1 year of dupilumab-treated AD versus 16 weeks of dupilumab-treated AD.
  • Table S12 (Microsoft Excel format). Differential protein expression of proteomic multiplex assays from suction blister fluid samples.
  • Table S14 (Microsoft Excel format). Differential protein expression of proteomic multiplex assays from serum samples.
  • Table S15. Raw data file (Excel spreadsheet)

Source Link